The diabetes medication vildagliptin may be beneficial in patients with type 2 diabetes and heart failure, but its cardiovascular safety is uncertain, a placebo-controlled trial showed (Medpage)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
